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Abstract 
The treatment of hepatitis C virus (HCV) infection has been revolutionised by the 
advent of oral, well-tolerated, direct acting antiviral therapies (DAA), with high cure 
rates. However, in some scenarios, HCV resistance to antiviral therapies may have 
an impact on treatment success. Public Health England’s HCV Resistance Group 
was established to support clinicians treating people with HCV, where the issue of 
resistance may be a factor in clinical decision-making, and this review includes the 
Group’s current recommendations on the use of HCV resistance testing. The authors 
describe the principles behind and approach to HCV resistance testing and consider 
evidence from in vitro studies, clinical trials and real world cohorts on the impact of 
HCV resistance on treatment outcomes for particular DAA regimens. Five scenarios 
are identified in the UK and similar settings, where, in the Group’s opinion, 
resistance testing should be performed. 
Key words 
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A. Introduction to HCV resistance testing
1. Background
The management of hepatitis C virus (HCV) infection has been revolutionised 
by the advent of direct-acting antiviral (DAA) therapies. These all oral, well-
tolerated therapies typically result in sustained virological response (SVR) 
rates of >95%. SVR is usually assessed at 12 weeks after cessation of 
antiviral therapy and is referred to as ‘SVR12’. DAA regimens may exert 
differential activity according to the viral genotype and subtype and the 
presence of viral drug resistance, and an understanding of the principles of 
resistance testing is therefore required. 
This review aims to support clinicians treating people with HCV in settings 
where the issue of resistance may be a factor in clinical-decision making. 
Where guidance is presented, this represents the opinion of the UK’s Public 
Health England (PHE) HCV Resistance Group, a panel of experts who have 
considered data from in vitro studies, phase II and III clinical trials and real 
world studies. In general, data supporting the use of resistance testing have 
been included where the presence of resistance may result in increased 
virological failure with an SVR12 rate of less than 95%. 
The Group also recognises the increasing availability of second-generation 
DAA regimens, which exert activity across major HCV genotypes and may 
retain high antiviral potency in the presence of viral resistance-associated 
substitutions (RAS). The use of these newer regimens underpins a treatment 
strategy that may remove the requirement for viral genotype determination 
and resistance testing, thereby permitting treatment scale up (1). However, in 
many settings,  including England, restrictions are currently imposed on the 
choice of DAA combinations by national organisations responsible for 
implementing HCV treatment programs, and scenarios in which pre-therapy 
RAS testing may be appropriate are therefore still common. 
It is emphasised that this review does not seek to provide an overarching 
strategy for HCV elimination or to recommend the use of one DAA regimen 
over another. Clinicians wishing to access resources on these topics are 
advised to consult treatment guidelines (1, 2) or policy documents available 
from other sources (3).  
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2. Mechanisms of viral resistance
HCV virology 
HCV is an enveloped, single-stranded, positive-sense RNA virus of the family 
Flaviviridae and has a genome length of approximately 9.6 kilobases. As a 
consequence of the low fidelity of the viral RNA-dependent RNA polymerase 
(RdRp), multiple errors are introduced into progeny viruses during virus RNA 
replication. The high error rate, in conjunction with a high turnover and 
progeny number (1012 virions/day) (4, 5), results in a large number of viral 
variants, harbouring different mutations, which coexist within the same host. 
This group of genetically-related viruses is commonly termed a quasispecies. 
Some of these nucleotide substitutions result in amino acid variants that 
confer a selective replication advantage in the presence of antiviral drug 
pressure. Amino acid substitutions thus may change the susceptibility of the 
virus to one or more drugs and, in this context, the variant amino acid is 
referred to as a RAS. Such RAS-harbouring variants are preferentially 
selected for, or enriched from baseline, following unsuccessful DAA therapy. 
Antiviral resistance 
Currently-available DAA inhibit one of three virally-encoded proteins: the 
NS3/4A protease complex, the NS5A protein (required for viral replication 
and assembly) and the NS5B RdRp. Of note, NS5B inhibitors may exert their 
effect either as competitive nucleotide analogues (NA) or as nonnucleoside 
allosteric (non-NA) inhibitors. HCV exhibits a high tolerance for RAS in the 
NS3 and NS5A genes, which can be accommodated without loss of 
replicative capacity (fitness). These RAS are therefore common in DAA-naïve 
populations, with a prevalence of up to 50% and 15% respectively, as 
detected by population sequencing (6, 7). Non-NA NS5B RAS have also 
been reported in up to 30% of DAA-naïve individuals (8). By contrast, NA 
NS5B RAS are rarely observed (1-3%), probably reflecting the loss of fitness 
which they impart. In particular, nucleotide substitutions in the highly 
conserved active site of RdRp may effectively halt viral replication (9). 
Of the three drug classes, resistance to NS5A inhibitors is clinically the most 
important and prevalence in DAA-exposed populations may approach 100% 
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(10). This reflects the substantial impact of NS5A RAS on drug susceptibility, 
the high fitness of NS5A RAS-bearing variants, and the ability of such 
variants to persist for years even in the absence of drug pressure (11). NS3 
RAS may emerge during therapy with NS3 protease inhibitors, but tend to 
become undetectable within months of stopping NS3 inhibitor-containing 
therapy (12). Non-NA NS5B RAS also emerge frequently after unsuccessful 
DAA therapies, but are not clinically significant, as the only drug in this class 
is not indicated in DAA-exposed individuals (8). By contrast, variants 
harbouring NA NS5B RAS rarely emerge following exposure to an NS5B 
inhibitor (1% of virologic failures) and are quickly replaced by fitter, wild-type 
virus (9). 
RAS are typically divided into those that are drug-specific (conferring reduced 
susceptibility to one particular antiviral agent) and those that are class-
specific (conferring reduced susceptibility to ≥2 agents in the same class 
although not necessarily reducing susceptibility to all drugs of that class). 
3. Recommended types of resistance test
Two types of tests predict susceptibility to antiviral drugs based on an 
analysis of the viral genotype or phenotype (Figure 1). Genotypic 
susceptibility testing is recommended as it is fast and widely available in 
routine diagnostic laboratories (Box 1). Both Sanger (direct) sequencing and 
next generation sequencing (NGS) may be used. Where NGS is used, a 
frequency cut-off of 15% is recommended for interpretation, as RAS present 
at lower frequency are unlikely to impact on SVR (1, 2, 6). For either platform, 
it is critical that results are made available in a timely fashion and do not 
delay treatment initiation.  Phenotypic resistance testing is laborious and 
complicated, and currently only available in research settings.  
Figure 1a. Methods for antiviral resistance testing of virus isolated from HCV-
infected individuals. 
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Genotypic antiviral resistance testing involves the detection of known drug resistance-
associated substitutions in the virus genome using Sanger or next generation (NGS) 
sequencing methods.  Either a fragment or the full length HCV genome may be sequenced. 
The product is then compared with a database of mutations reported previously as being 
associated with drug resistance in clinical trials and/or in vitro studies. Through this 
comparison, a ‘virtual phenotype’ for the sequence of interest is generated with predicted 
antiviral susceptibilities. 
Direct sequencing involves reverse transcription and PCR amplification of usually short (0.2 -
2.0 kilobase) segments of the NS3, NS5A and/or NS5B genes followed by Sanger 
sequencing. Most NGS assays use massive parallel sequencing of short fragments, which 
together encompass the whole or part of the HCV genome. The large number of sequencing 
products are aligned to a reference genome and software is used to identify RAS. The cut-off 
for HCV RNA level in the sample selected for resistance testing varies according to assay. 
Whilst some assays will use a lower limit of 100-300 IU/mL, others may require a HCV RNA 
level of at least 1000 IU/mL in order for genome amplification to be reliably performed. The 
cut-off should therefore be confirmed with the testing laboratory. Stored frozen samples can 
be tested without the need to recall individuals. 
Phenotypic testing involves a direct measure of virus susceptibility in cell culture by cloning 
of parts of the virus genome into a sub-fragment of the HCV genome that has the capability 
to replicate viral RNA in tissue culture cells (the sub-genomic HCV replicon assay).  The 
extent of viral replication can be measured by expression of a reporter gene and, using this 
approach, drug susceptibility and viral fitness can be assessed. RAS-bearing isolates are 
challenged with increasing concentrations of antivirals to establish fold changes, such as 
IC50, the concentration at which 50% of viral replication is inhibited with respect to wild-type. 
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Of note, HCV cell culture systems for the culture of HCV directly from clinical isolates are still 
in the early stages of development and are therefore not yet widely used. 
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Figure 1b. The ‘virtual phenotype’, an example for HCV genotype 1a, from HCV 
GLUE(13) 
1. RAS are assigned to one of three categories according to the strength of evidence for drug
resistance. Category I RAS have the strongest evidence: either (a) in vitro resistance level ≥ 5
and found at baseline or treatment-emergent in vivo, or (b) both found at baseline and
treatment-emergent. Category II: in vitro level ≥ 50 or found at baseline or treatment-
emergent. Category III: in vitro level ≥ 5
2. Resistance level to a given drug is assigned to one of four categories. Strong resistance: any
category I RAS. Moderate resistance: any category II RAS. Weak resistance: any category III
RAS. Susceptible: none of the above.
Drug category Drug 
Resistance-associated substitutions 
(RAS)
1
Resistance 
level
2
Category I 
Category 
II 
Category 
III 
NS3/4A protease 
inhibitors 
glecaprevir - - - Susceptible 
voxilaprevir - - - Susceptible 
NS5A inhibitors elbasvir L31M (31.7%) - - Strong 
resistance 
pibrentasvir - - - Susceptible 
velpatasvir L31M (31.7%) - - Strong 
resistance 
NS5B RNA polymerase 
inhibitors 
sofosbuvir - - - Susceptible 
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Box 1. General recommendations on the use of sequencing in the 
management of people with HCV   
Types of resistance test 
Where resistance testing is performed, Sanger sequencing or next generation 
sequencing (NGS) methods are recommended. 
Timing of resistance tests 
Where resistance testing is performed prior to re-treatment in individuals previously 
exposed to DAA, this should be done on a sample taken as close as possible to the 
planned re-treatment start date. 
Methods of genotype assignment 
Genotyping should be performed with Sanger sequencing of NS5B or core, or by 
whole genome sequencing with NGS. 
Recombinants 
If a sample has been assigned to genotype 2 through sequencing of core, additional 
sequencing, such as NS5B sequencing or whole genome sequencing should be 
performed, prior to the use of a genotype-specific DAA regimen, in order to exclude 
a recombinant form. 
Mixed infection 
Viral sequencing should be performed where treatment failure is suspected due to 
an undiagnosed initial mixed infection. Testing of the stored pre-therapy sample 
should be undertaken in conjunction with the failure specimen. 
Reinfection 
Viral sequencing should be performed where reinfection is suspected as a cause of 
recurrence of viraemia during or on completion of therapy. This should be performed 
on the pre-treatment and failure specimens. 
Specimen storage 
Pre-treatment specimens should be stored for a minimum of six months to allow 
retrospective sequencing to be performed when required. 
4. Indications for resistance testing
In certain scenarios, RAS testing is recommended in DAA-naïve individuals 
prior to initiation of therapy, given the reduction in SVR12 rates that may be 
associated with baseline RAS (See Table 1). In cases of failure of DAA-
based therapy, testing may inform the choice of the re-treatment regimen. If 
RAS testing is performed, this should be carried out using a blood sample 
taken as close as possible to the planned retreatment start date. This is to 
take into account the likelihood of the RAS-harbouring variant becoming a 
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minor population over time with the dominant population having wild-type 
characteristics.  
Table 1. Pre-treatment NS5A RAS testing in DAA-naïve individuals (14-16) 
Drug regimen 
Genotype 1a Genotype 3a 
Pre-
therapy 
NS5A RAS 
testing 
RAS Management 
Pre-
therapy 
NS5A RAS 
testing 
RAS Management 
Elbasvir / 
grazoprevir Yes 
Positions 28, 
30, 31, 58, 
93
1
Extend to 16 
weeks and 
add WB 
ribavirin Not used 
Velpatasvir 
/sofosbuvir No 
Yes, if 
cirrhosis Y93H 
Add WB 
ribavirin 
Pibrentasvir / 
glecaprevir No No 
Ledipasvir/ 
sofosbuvir No Not used 
Ombitasvir / 
paritaprevir 
ritonavir/ 
dasabuvir No Not used 
1. M28A/G/S/T/V, Q30D/E/G/H/K/R/Y, L31F/I/M/V, H58D, Y93C/H/N/S
WB = weight based 
5. Interpretation of results
The potential impact of RAS on predicted response to DAA therapy may vary 
according to: 
 patient characteristics, including the presence of hepatic cirrhosis
(particularly if decompensated) and prior treatment history
 proposed DAA regimen and interactions with concomitant medications
viral characteristics, such as the genotype, subtype (where not commonly
prevalent within available datasets, such as 1l, 3b or 4r), the decrease in drug
susceptibility conferred by specific RAS, the number and pattern of RAS, any
associated fitness costs and the pre-treatment HCV RNA level
Treatment decisions should therefore not be made solely on the basis of
resistance testing and the interplay between these factors should be taken
into account. In particular, RAS are more likely to be of clinical relevance in
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individuals with additional adverse factors, such as cirrhosis and prior DAA 
exposure 
Management approaches following identification of RAS 
Where clinically-relevant RAS are identified, actions may involve one or more 
of: 
 prolongation of DAA therapy
 the inclusion of a class of DAA to which the patient has not been exposed
 intensification with an additional drug, such as weight-based ribavirin
 avoidance of a particular DAA regimen
If resources permit, ribavirin-sparing strategies are preferable to avoid 
possible ribavirin-associated toxicities (1, 2) 
The decision to offer DAA treatment to a patient with baseline RAS should 
involve consideration of these additional factors and the predicted reduction 
in SVR12 rate, if known. For patients with decompensated liver disease, 
treatment selection may be impacted by contraindications to certain drugs, 
such as NS3 protease inhibitors. The suitability of the patient for liver 
transplantation and the possible impact of transplantation on future timing 
and responsiveness to antiviral treatment should be considered. 
Interpretation of multiple resistance tests 
Where more than one resistance test has been performed for the same HCV 
infection, it may be necessary to consider the cumulative results of both 
current and prior RAS testing, particularly in the context of NS5A RAS. This 
may be less relevant for NA NS5B or NS3 RAS, particularly if years have 
elapsed between the two tests, in view of the lower likelihood of these RAS 
persisting in the absence of drug pressure. 
6. Genotyping
HCV is currently classified into eight genotypes (17), which differ by at least 
30% in their nucleotide sequence. Each genotype is further subdivided into 
subtypes, which may differ by greater than 15% in their nucleotide 
composition, with >80 currently recognised (18). Accurate determination of 
genotype/subtype can be critical, as this may impact response to DAA 
12 
therapies. Recommended methods of genotyping are Sanger sequencing of 
NS5B or core, and whole genome sequencing by NGS, which have been 
shown to produce accurate and reproducible results (2) (19). Other platforms, 
including Line Probe assays and 5’UTR PCR amplification, are not 
recommended, as they may be insufficiently sensitive to be able to 
distinguish between subtypes (20).  
Clinical trials have notably focused on HCV genotypes 1a, 1b and 3a, 
reflecting the distribution of HCV genotypes in high income settings, with 
limited data presented for other genotypes and subtypes. There is 
consequently less evidence to support the interpretation of RAS in “rarer” 
subtypes such as those prevalent in lower income countries, including but not 
limited to subtypes 1l (West Africa) (21, 22), 3b (China and South East Asia 
(23)), 4r (all regions of Africa) (24-28), 6a-x (China and South East Asia )(29), 
7 (Democratic Republic of Congo) (30) and 8 (India) (17). More data on the 
sensitivity of these HCV subtypes to current DAA regimens are needed.  
Rarely, recombinant strains of HCV have been described, representing HCV 
genomes comprised of two different viral genotypes. The recombinant 2k/1b 
is the most frequently observed in real world settings, particularly in countries 
of the former USSR, in which the 5’ end of genotype 2k is combined with the 
3’ end (including the non-structural genes) of genotype 1b. Therefore, where 
genotype-specific DAA regimens are used, any specimen provisionally 
assigned by core or 5’UTR (a non-recommended method) sequencing to 
genotype 2 should be additionally sequenced for NS5B or for the whole 
genome prior to initiating therapy, in order to exclude a recombinant form 
(31). 
7. Mixed infection
A proportion of individuals with HCV are infected with two or more different 
HCV genotypes or subtypes (‘mixed infection’). Mixed infection prevalence 
varies between 1-30% (32-34). This range likely reflects the heterogeneity of 
the populations sampled, with the highest rates in groups with frequent HCV 
exposures, such as people who inject drugs (PWID). Furthermore, 
identification of mixed infection may be limited by the sequencing method, as 
Sanger sequencing fails to detect minor populations. 
Where individuals with mixed HCV infection receive therapy with a genotype-
specific DAA regimen, the response of each infecting genotype may be 
discordant. Thus, treatment failure may represent the emergence of a 
previously-undetected minor population following clearance of the dominant 
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genotype. The newly-identified, emergent genotype may be incorrectly 
interpreted as a new infection and, in addition, may have developed RAS 
following DAA exposure. Viral sequencing to confirm the genotype should 
therefore be performed where treatment failure due to an undiagnosed initial 
mixed infection is suspected, particularly following failure with a genotype-
specific DAA regimen, such as in individuals with multiple episodes of risk. 
Testing of the stored pre-therapy sample should be undertaken in conjunction 
with the failure specimen. NGS may be preferable in this scenario, given the 
greater sequencing information it provides. Where mixed infections are 
identified, use of a DAA regimen, which is active across major genotypes, 
increases the likelihood for successful cure of both infecting genotypes. 
To enable parallel testing of the pre-therapy and failure specimens, pre-
treatment samples should be stored for a minimum of six months. They may 
then be tested retrospectively, where this is indicated. 
8. Reinfection
Reinfection after spontaneous or treatment-induced virus clearance is 
common amongst populations with repeated exposures to HCV, such as men 
who have sex with men (MSM) living with HIV, and PWID (35-37). If 
recurrence of viraemia is observed during or on completion of therapy, viral 
sequencing of the failure and pre-treatment specimens can help differentiate 
between relapse and reinfection, especially where recurrence of viraemia 
occurs with the same subtype. Clustering of the failure and pre-treatment 
sequences on a phylogenetic tree is observed in cases of relapse but not 
reinfection, unless reinfection occurred from the same source. The depth and 
breadth of coverage of sequencing data provided by NGS may improve the 
resolution of the tree, with increased ability to differentiate relapse from 
reinfection. 
9. Difficult-to-engage patient groups
Many people living with HCV are not currently engaged with HCV services. 
This may be a result of difficulties attending follow-up after a positive HCV 
diagnosis, or because the diagnosis has not yet been made. Patient groups 
who may have difficulty accessing HCV services include PWID, people with 
mental health problems and people who are homeless (38). For example, 
only around half of PWID sampled in the UK’s PHE Unlinked Anonymous 
Survey in 2016 were aware of their positive HCV antibody status (39). 
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For individuals from these groups, it is particularly critical that treatment be 
available as soon as possible after diagnosis to minimise the risk of loss to 
follow-up. Any benefit of performing resistance testing must be weighed 
against the delay in initiating therapy. Early use of a DAA regimen, which 
both exerts activity across major genotypes and retains potency against 
RAS-harbouring virus (i.e., has a high genetic barrier to resistance), avoids 
the requirement for viral genotyping and resistance testing and facilitates 
early initiation of treatment in these individuals.  
 
 
 
B. HCV resistance testing prior to the use of specific DAA: 
treatment-naïve individuals and those for whom non-NS5A 
inhibitor-containing therapy has previously failed 
1. Sofosbuvir-ledipasvir 
Early clinical trials data for treatment outcomes with sofosbuvir plus the first 
generation NS5A inhibitor ledipasvir suggested ledipasvir RAS may reduce SVR12 
for individuals with genotype 1a infection in some scenarios, including those 
receiving a shortened 8 week treatment course (7) those previously exposed to 
pegylated interferon-ribavirin, or those with cirrhosis (7, 40) receiving 12 weeks of 
therapy. Addition of ribavirin and/or extension of therapy was suggested to restore a 
high SVR12 rate. However, in a large NHS England cohort including HCV genotype 
1a-infected patients, high SVR12 rates for both sofosbuvir-ledipasvir (94-98%) and 
sofosbuvir-ledipasvir with ribavirin (93-96%) were reported. RAS testing is thought 
not to have been widely used in determining DAA regimens in this cohort. These 
data suggest routine pre-therapy resistance testing may not be necessary (41).  
Of note, data on the effect of RAS on SVR12 outcomes with sofosbuvir-ledipasvir in 
‘rare’ subtypes such as genotypes 4-6, are few, and mostly from studies with small 
numbers of individuals (21, 42-45). Early reports suggest a greater prevalence of 
multiple NS5A RAS in therapy-naïve individuals in these subtypes, which may 
account for lower SVR12 rates. For example, SVR12 in a Rwandan population was 
54% for subtype 4r with 12 weeks of sofosbuvir-ledipasvir (24). The combination of 
NS5A RAS L28V+L30R+/-L31M, frequently identified pre-treatment, together with 
minor populations of NS5B RAS, such as the sofosbuvir mutation S282C/T, may 
underpin the reduced SVR in this subtype (26). 
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2. Elbasvir-grazoprevir
The regimen of elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A 
inhibitor, with or without ribavirin, is licensed for the treatment of genotype 1a, 
1b and 4 infections. In replicon systems, NS5A RAS conferring ≥100 fold 
reduction in elbasvir susceptibility in genotype 1a include Q30D/R, L31F/V, 
del32 and Y93C/H/N (15, 46-48). A pooled analysis of phase II and III clinical 
trials reporting outcomes following 12 weeks of elbasvir-grazoprevir, including 
treatment-naïve individuals and those previously treated with pegylated 
interferon-ribavirin +/- protease inhibitor infected with HCV genotype 1a, both 
with and without cirrhosis, identified an SVR12 of 70% (39/56) versus 98% 
(441/450) for those with and without baseline elbasvir RAS, respectively (15). 
Of note, M28V was the commonest variant, and was associated with a 
reduced SVR12 (86%). Based on data from only 6 individuals, prolongation 
of the regimen to 16 weeks and intensification with ribavirin appeared to 
increase efficacy in those with baseline elbasvir RAS. Subsequent analyses 
showed that a low baseline HCV RNA level (<800,000 IU/mL) may reduce 
the impact of NS5A RAS, with 8/8 individuals with elbasvir RAS and an HCV 
RNA <800,000 IU/mL achieving SVR12 (49). Of note, however, use of 
baseline viral load in place of RAS testing for treatment decisions may lead to 
unnecessary use of ribavirin (50). An effect of NS5A RAS on SVR12 was not 
seen for genotypes 1b or 4 (15). 
3. Sofosbuvir-velpatasvir
The combination of sofosbuvir with the second generation NS5A inhibitor, 
velpatasvir, is licensed for treating genotypes 1-6. In vitro, RAS conferring 
high (>100x EC50) fold changes to velpatasvir include L31V and 
Y93C/H/N/R/W in genotype 1a, and L31V and Y93H/S in genotype 3a (46, 
51, 52). 
Randomised controlled studies found no impact of RAS for genotypes 1, 2, 4 
and 6 in individuals with and without compensated cirrhosis, including those 
with prior exposure to pegylated interferon-ribavirin with or without a protease 
inhibitor (16). However, for genotype 3 (predominantly subtype 3a), SVR12 
was 86% (19/22) and 98% (445/454) for those with and without Y93H, 
respectively. Previous interferon-containing treatment and/or cirrhosis were 
additional factors in reducing treatment efficacy; in particular, SVR12 was 
only 67% (4/6) in the small number with cirrhosis and Y93H (16, 53). Further 
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pooled analyses of phase II and III studies in genotype 3a-infected patients 
with compensated cirrhosis identified an SVR12 of only 80% where baseline 
NS5A RAS were present vs 94% overall (54).  
 
By contrast, results from real world trials of sofosbuvir-velpatasvir in patients 
with genotype 3 infection, compensated cirrhosis and baseline Y93H are 
conflicting as to its impact on SVR (55) (56).  
 
However, data from England’s National Health Service (NHS) (n=470) 
reported an SVR12 rate of 95% vs 92-93% for those with compensated 
cirrhosis and genotype 3 receiving sofosbuvir-velpatasvir with and without 
ribavirin, respectively (41) and, although resistance data were not available, 
this may further support the approach for NS5A RAS testing in the UK 
setting, with addition of ribavirin or use of an alternative regimen where Y93H 
is identified.  
  
Treatment outcomes with sofosbuvir-velpatasvir may also be affected by pre-
treatment RAS in other patient groups with adverse characteristics. In the 
ASTRAL-4 study (n=267), SVR12 was reduced in patients with 
decompensated cirrhosis infected with genotype 1 (subtypes 1a or 1b) and 
harbouring NS5A RAS, who received 12 weeks of sofosbuvir-velpatasvir 
(80% vs 96% with and without NS5A RAS). This effect of NS5A RAS could 
be partially overcome by extension to 24 weeks of treatment (SVR12 90%) or 
fully overcome by addition of ribavirin (SVR12 98%) (57). In the NHS England 
cohort, the SVR12 rate in individuals with genotype 3 infection (subtype not 
reported) was only 84% and 86% for those with decompensated cirrhosis 
receiving therapy with sofosbuvir-velpatasvir with and without ribavirin, 
respectively (41). The impact of RAS on SVR in this group remains to be 
determined. 
A high prevalence of pre-treatment NS5A RAS in ‘rarer’ subtypes, such as 
A30K+L31M in genotype 3b, may also reduce SVR12 with sofosbuvir-
velpatasvir, particularly in individuals with cirrhosis (58) (23). However, the 
optimal treatment approach in these individuals has not yet been identified. 
 
 
4. Other regimens 
For ritonavir-boosted paritaprevir, ombitasvir and dasabuvir, and for glecaprevir-
pibrentasvir available data suggest routine pre-therapy RAS testing is unlikely to 
offer benefit in DAA-naïve individuals (59) although further data are required on 
17 
treatment outcomes with glecaprevir-pibrentasvir in individuals infected with rare 
subtypes, such as 3b  , where multiple pre-treatment NS5A RAS are common and 
SVR12 rates reduced (60). NS3 and NS5A RAS testing is recommended in 
individuals with prior exposure to NS3 protease inhibitors who are retreated with 
glecaprevir-pibrentasvir, as discussed in Section C (61, 62). 
C. Retreatment of individuals for whom prior NS5A inhibitor-
containing therapy has failed
Background 
Approximately 5% of individuals receiving DAA therapies in the real world 
setting do not achieve SVR12 (1, 2, 41). All currently recommended regimens 
include NS5A inhibitors, with the consequent high probability of NS5A RAS in 
DAA-exposed patients. 
Most of these individuals achieve an on-treatment response with 
undetectable virus at end-of-treatment, followed by viral rebound (relapse), 
which in many cases represents the emergence of a DAA-resistant viral 
strain. Other possible patterns of failure are viral rebound during therapy 
(breakthrough) or failure of the viral load to suppress (non-response). 
Reinfection or initial mixed infection may be alternative explanations for 
recurrence of viraemia. 
There are currently limited data to inform the optimal strategies for 
retreatment of individuals experiencing failure particularly with second 
generation DAA therapies, However, the improved genetic barrier to 
resistance of triple class, second generation DAA combinations, often 
overcomes the effect of RAS.  
Sofosbuvir-velpatasvir-voxilaprevir 
In two phase III randomised controlled studies in individuals with and without 
compensated cirrhosis, infected with genotypes 1-3 and previously exposed 
to DAA, including first generation NS5A inhibitors (POLARIS 1 and 4), 
SVR12 following 12 weeks of therapy with sofosbuvir-velpatasvir-voxilaprevir 
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was >95%. There was no impact of baseline RAS, despite a high pre-
treatment prevalence of NS3 and NS5A RAS (63). Treatment-emergent RAS 
were also uncommon (1/7 individuals with relapse). The lowest SVR12 rate 
(90%) was seen in HCV genotype 3a infected individuals with cirrhosis and 
baseline NS5A RAS. An integrated resistance analysis of four phase II 
studies with this drug combination in DAA-naïve and –experienced 
individuals infected with HCV genotypes 1-4 and 6, also confirmed the lack of 
impact of baseline RAS on SVR12 (64). 
 
Real world cohorts have confirmed SVR12 > 90% with this regimen, mainly 
for genotypes 1-4, following unsuccessful therapy with first generation NS5A 
inhibitors (65-68) or unspecified NS5A inhibitors (69, 70). However, a lower 
SVR12 (9/13, 69%) was reported for genotype 3 infected patients (subtypes 
not presented) with cirrhosis (71)  . Regarding second generation NS5A 
inhibitor exposed individuals, lower SVR12 rates (83-86%) were reported in 
individuals with genotypes 1-3 previously exposed to sofosbuvir-velpatasvir, 
(72), but with no impact of this prior combination in other studies (SVR 94-
100%) (73),(74) emphasising the need for further retreatment outcome 
datasets in sofosbuvir-velpatasvir exposed patients, including resistance 
data. High SVR (94%) was reported in glecaprevir-pibrentasvir exposed 
individuals who received retreatment with sofosbuvir-velpatasvir-voxilaprevir 
(75).  Notably, however, voxilaprevir and sofosbuvir are contraindicated in 
individuals with decompensated cirrhosis or an eGFR <30 mL/min/1.73m2, 
respectively.  
 
Glecaprevir-pibrentasvir 
Glecaprevir-pibrentasvir has also been used to treat NS5A inhibitor-
experienced individuals. One phase III study (Magellan-1, Part 2) found 
reduced SVR12 (83%) in genotype 1 infected individuals with pre-therapy 
NS5A RAS receiving 12 weeks of therapy, which could be overcome by 
extension to 16 weeks of treatment (SVR12 96%). The presence of 
NS3+NS5A RAS led to low SVR12 even with the extended duration (76) 
Consistent with these findings, a phase II trial of 12 weeks of glecaprevir-
pibrentasvir (Magellan-1, Part-1) reported lower SVR12 (91-93%) in those 
with NS5A+/-NS3 RAS compared to those with NS3 RAS alone (100%) (61) 
 
A further study including genotype 1a-infected individuals with and without 
compensated cirrhosis, who were previously exposed to an NS5A inhibitor 
plus sofosbuvir, compared 12 versus 16 weeks of glecaprevir-pibrentasvir +/- 
ribavirin. Higher SVR12 (97% and 94% for those with and without cirrhosis) 
was found in the 16 week arm compared to those receiving the shorter 
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course (86%-90%). SVR12 was also lower in those with NS5A RAS pre-
treatment (88% vs 97%), although this difference was not statistically 
significant (77). Treatment-emergent NS3 and/or NS5A resistance mutations 
were frequently observed in those not achieving SVR12, including the 
deletion in NS5A at position 32, which is associated with >1000 fold 
resistance to all NS5A inhibitors (46). This deletion was also observed in 
DAA-exposed genotype 1b cohorts and conferred resistance to glecaprevir-
pibrentasvir (78, 79). 
Sofosbuvir-velpatasvir 
A phase II study evaluated outcome with 24 weeks of sofosbuvir-velpatasvir 
and ribavirin, in individuals with and without compensated cirrhosis, infected 
with genotypes 1, 2 or 3, who had failed first line NS5A-inhibitor containing 
therapy. Overall SVR12 was 91% (63/69) with no impact of baseline NS5A 
RAS for genotypes 1 and 2. However, for genotype 3a, SVR12 was 77% 
(10/13) and 100% (4/4) in those with and without baseline NS5A RAS, 
respectively (80). In a real world study of 24 weeks of sofosbuvir-velpatasvir 
+/- ribavirin, mostly in individuals with cirrhosis (of unknown stage) infected 
with genotypes 1-4, including those exposed to NS5A inhibitors, an SVR12 of 
84% (26/31) was reported overall, but was 57% (4/7) in those with baseline 
L31F/I/M. RAS impact by genotype was not reported (81). Owing to lower 
SVR compared to other regimens, sofosbuvir-velpatasvir is not 
recommended in NS5A inhibitor exposed patients in international guidelines, 
except in individuals with decompensated cirrhosis, in whom protease 
inhibitors are contraindicated. However, resistance data in this setting are not 
yet available. 
Sofosbuvir-elbasvir-grazoprevir 
Although the combination of sofosbuvir-elbasvir-grazoprevir, with or without 
ribavirin, is not currently recommended for DAA-experienced patients in 
guidelines, early data suggest it may be effective. SVR rates of 96-100% 
have been reported in trials, including individuals with genotypes 1-4 
infection, compensated cirrhosis and with no impact of NS5A +/- NS3 RAS 
on outcomes (82)  (83)(84). However, a larger cohort with this combination, 
including genotype 1a-infected individuals previously exposed to ledipasvir-
sofosbuvir, reported an SVR12 of 90% vs 100%  in those with and without 
pre-retreatment elbasvir RAS, respectively (68) . 
Sofosbuvir-glecaprevir-pibrentasvir 
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In a phase III study (Magellan-3), individuals with or without compensated 
cirrhosis, who had previously received therapy with glecaprevir-pibrentasvir, 
were retreated with sofosbuvir-glecaprevir-pibrentasvir plus ribavirin. Most 
individuals had genotype 1a or 3a infection and received 16 weeks of 
therapy. Despite a high baseline prevalence of NS5A RAS, SVR12 was 96% 
(22/23) (85). Pibrentasvir has the highest genetic barrier to resistance of the 
NS5A inhibitors (46) and therefore the use of this regimen, with extended 
duration +/- inclusion of ribavirin, may become an important option for 
retreatment of patients exposed to second generation and/or triple class DAA 
regimens. However, this requires evaluation in clinical studies. 
 
D. Discussion  
In the current UK landscape, DAA regimens are recommended, for which pre-
treatment RAS may impact SVR12 in certain scenarios. In this and similar settings, 
the writing group suggests a pragmatic approach to the use of resistance testing. 
Where access to resistance testing is limited, or where the clinical setting requires 
rapid initiation of therapy without waiting for the results of specialised testing, RAS 
testing may be omitted. Where RAS testing is accessible, this should be performed 
in selected scenarios (Box 2). Although RAS testing may not influence the immediate 
treatment decision in all cases, results may be helpful either to the particular patient 
or to others in the future. Some of the data, in particular analyses of the NHS 
England registry, are only available in preliminary form, without peer review, and this 
must be considered a limitation in interpreting clinical significance.  
The writing group acknowledges that these recommendations differ from those of 
international bodies, including the European Association of the Study of the Liver 
(EASL) and the American Association for the Study of Liver Diseases – Infectious 
Diseases Society of America (AASLD-IDSA)(1, 2). EASL guidelines do not 
recommend RAS testing in therapy naïve individuals and favour the use of ribavirin-
free DAA regimens, citing the efficacy of newer regimens against RAS-harbouring 
virus, the lack of access to resistance testing and the absence of a consensus on 
interpretation of results. This is an attractive strategy, but not entirely applicable in 
the current UK context, given the widespread use of regimens in circumstances 
where there may be a benefit in including ribavirin, the more restricted access to 
newer agents, including sofosbuvir-velpatasvir-voxilaprevir, and the availability of 
resistance testing at multiple centres. Baseline RAS testing therefore enables certain 
groups to be spared unnecessary ribavirin exposure, such as those with genotype 3a 
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infection and compensated cirrhosis receiving sofosbuvir-velpatasvir, who do not 
have the NS5A Y93H mutation.  
AASLD-IDSA guidelines differ from those of EASL on the indications for RAS testing, 
with recommendations for NS5A testing prior to elbasvir-grazoprevir in therapy-naïve 
patients with genotype 1a infection and in those with genotype 3a infection and 
cirrhosis or prior pegylated-interferon-ribavirin exposure prior to sofosbuvir-
velpatasvir use, based on data outlined above (15, 53). Thus, the recommendations 
of PHE’s writing group align more closely with those of AASLD-IDSA for DAA-naïve 
individuals, reflecting similarities in treatment landscapes.  
By contrast, EASL does recommend RAS testing in DAA- experienced individuals 
prior to re-treatment to assist in optimising the re-treatment regimen, referring to the 
current lack of data to guide selection and duration of treatment, particularly in those 
with NS5A inhibitor exposure. Conversely, AASLD-IDSA guidelines do not 
recommend RAS testing in this setting, citing successful outcomes from POLARIS-1 
and POLARIS-4. PHE’s recommendations thus align more closely with those of 
EASL for this cohort. 
For individuals with decompensated cirrhosis there is similarly a paucity of data to 
guide the use of pre-therapy RAS testing. Neither EASL nor AASLD-IDSA 
recommend baseline resistance testing and advise that ribavirin, if tolerated, should 
be included in all regimens (57, 86). By contrast, PHE’s writing group favours RAS 
testing based on limited data which suggest that certain individuals with 
decompensated cirrhosis, who do not have resistant virus, may not require ribavirin 
(57) as well as the need to gather further data across genotypes to guide best
practice. The requirement for additional data also informs the writing group’s view 
that RAS testing should be performed in those with ‘rare’ subtypes, a group which is 
not specifically addressed in the EASL or AASLD-IDSA guidelines.  
Recommendations on RAS testing are likely to change as more detailed analyses of 
existing data, as well as newer data, become available. In particular, further studies 
are needed to address current unmet needs, including the impact of resistance on 
SVR outcomes in individuals with ‘rare’ subtypes, the impact of RAS on re-treatment 
outcomes according to the timeline between first and second DAA regimens and the 
optimal re-treatment regimens both for individuals exposed to second generation 
DAA as well as for NS5A inhibitor-exposed individuals with decompensated 
cirrhosis. 
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Box 2. Scenarios where resistance testing is recommended prior 
to DAA therapy  
1. NS5A RAS in GT1a prior to Elbasvir/Grazoprevir.
Treatment-naïve individuals and those exposed to PEG/RBV+/-PI
Where elbasvir RAS are identified, patients should receive 16 weeks of
therapy with ribavirin or an alternative regimen.
2. NS5A RAS in GT3a with compensated cirrhosis prior to
Sofosbuvir/Velpatasvir.
Treatment-naïve individuals and those exposed to PEG/RBV+/-PI
Where Y93H is identified, patients should receive 12 weeks of therapy with
ribavirin, 24 weeks of therapy, or an alternative regimen.
3. NS5A RAS in all patients with decompensated cirrhosis prior to DAA
therapy.
This is to identify patients who may benefit from ribavirin or extension of
therapy, or, in some cases, to guide future treatment decisions.
4. NS5A RAS in subtypes not commonly found in high income countries,
including genotypes 4, 5 and 6.
This is to guide future treatment decisions, as resistance data are currently
lacking.
5. NS3 and NS5A RAS in all patients with previous exposure to NS3 and/or
NS5A inhibitors, prior to re-treatment.
This is either to determine duration of therapy, in some cases, or to guide
future treatment decisions.
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